Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.1M Sell
117,597
-4,937
-4% -$578K 1.16% 23
2026
Q1
$14.7M Buy
122,534
+3,147
+3% +$363K 1.22% 22
2025
Q4
$12.6M Buy
119,387
+477
+0.4% +$44.8K 1.05% 26
2025
Q3
$9.98M Buy
118,910
+875
+0.7% +$72.1K 0.86% 36
2025
Q2
$9.34M Buy
118,035
+2,284
+2% +$182K 0.87% 38
2025
Q1
$10.4M Buy
115,751
+1,890
+2% +$176K 1.04% 31
2024
Q4
$11.3M Buy
113,861
+1,251
+1% +$129K 1.11% 24
2024
Q3
$12.8M Buy
112,610
+35,321
+46% +$4.2M 1.15% 20
2024
Q2
$9.57M Sell
77,289
-30,810
-29% -$3.97M 1.04% 21
2024
Q1
$14.3M Buy
108,099
+33,541
+45% +$4.13M 1.43% 13
2023
Q4
$8.13M Buy
74,558
+4,228
+6% +$439K 1.05% 23
2023
Q3
$7.24M Buy
70,330
+29,210
+71% +$3.15M 1.05% 24
2023
Q2
$4.75M Sell
41,120
-970
-2% -$110K 0.89% 26
2023
Q1
$4.48M Buy
42,090
+4,408
+12% +$476K 0.93% 21
2022
Q4
$4.18M Buy
37,682
+1,432
+4% +$146K 1.01% 22
2022
Q3
$3.12M Buy
36,250
+305
+0.8% +$27.2K 0.83% 25
2022
Q2
$3.28M Buy
35,945
+3,872
+12% +$343K 0.84% 29
2022
Q1
$2.63M Buy
32,073
+10,582
+49% +$834K 0.59% 41
2021
Q4
$1.65M Sell
21,491
-221
-1% -$17.6K 0.35% 64
2021
Q3
$1.63M Sell
21,712
-500
-2% -$38K 0.37% 62
2021
Q2
$1.73M Sell
22,212
-2,984
-12% -$222K 0.39% 63
2021
Q1
$1.85M Buy
25,196
+19,267
+325% +$1.42M 0.46% 55
2020
Q4
$463K Sell
5,929
-365
-6% -$27.9K 0.12% 123
2020
Q3
$498K Sell
6,294
-388
-6% -$30.4K 0.11% 131
2020
Q2
$493K Sell
6,682
-21,256
-76% -$1.6M 0.11% 131
2020
Q1
$2.05M Sell
27,938
-1,686
-6% -$133K 0.58% 46
2019
Q4
$2.57M Buy
29,624
+3,759
+15% +$309K 0.59% 48
2019
Q3
$2.08M Buy
25,865
+2,212
+9% +$177K 0.61% 42
2019
Q2
$1.89M Buy
23,653
+376
+2% +$28.8K 0.53% 52
2019
Q1
$1.85M Buy
23,277
+13,166
+130% +$985K 0.57% 44
2018
Q4
$737K Buy
+10,111
New +$714K 0.34% 60

Other funds holding MRK

SlateStone Wealth's MRK Position: Q2 2026 in Review

SlateStone Wealth reduced its Merck (MRK) stake by 4% in Q2 2026, selling an estimated $578K and leaving 117,597 shares worth $15.1M. The position accounts for 1.16% of the portfolio, ranked #23.

SlateStone Wealth first reported a position in MRK in Q4 2018 and has held it in 31 quarters since. 1,533 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • SlateStone Wealth held 117,597 shares of Merck worth $15.1M as of Q2 2026.
  • SlateStone Wealth sold 4,937 Merck shares in Q2 2026, an estimated $578K.
  • Merck made up 1.16% of SlateStone Wealth's portfolio in Q2 2026, its #23 holding.
  • SlateStone Wealth first reported a position in Merck in Q4 2018 and has held it in 31 quarters since.
  • 1,533 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on SlateStone Wealth's 13F filing for Q2 2026, filed 20 Jul 2026.